SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • 1
    Sreerama L, Sladek NE. Class 1 and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the National Cancer Institute to screen for potentially useful antitumor agents. Adv Exp Med Biol 1997; 414: 8194.
  • 2
    Kastan MB, Schlaffer E, Russo JE, Colvin OM, Civin CI, Hilton J. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990; 75: 19471950.
  • 3
    Haselbeck RJ, Hoffman I, Duester G. Distinct functions fro Aldh1 and Raldh2 in the control of ligand production for embryonic retinoid signaling pathways. Dev Genet 1999; 4: 353364.
  • 4
    Moreb JS, Schweder M, Gray B, Zucali J, Zori R. In vitro selection for K562 cells with higher retrovirally mediated copy number of aldehyde dehydrogenase class-1 and higher resistance to 4-hydroperoxycyclophosphamide. Hum Gene Ther 1998; 9: 611619.
  • 5
    Moreb JS, Maccow C, Schweder M, Hecomovich J. Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro. J Pharmacol Exp Ther 2000; 293: 390396.
  • 6
    Moreb JS, Gabr A, Vartikar GR, Gowda S, Zucali JR, Mohuczy D. Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde. J Pharmacol Exp Ther 2005; 312: 339345.
  • 7
    Sladek NE, Kollander R, Sreerama L, Kiang DT. Cellular levels of aldehyde dehydrogenase (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: A retrospective study. Cancer Chemother Pharmacol 2002; 49: 309321.
  • 8
    Armstrong L, Stojkovic M, Dimmick I, et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 2004; 22: 11421151.
  • 9
    Hess DA, Meyerrose TE, Wirthlin L, et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004; 104: 16481655.
  • 10
    Jones RJ, Barber JP, Vala MS, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995; 10: 27422746.
  • 11
    Storms RW, Green PD, Safford KM, et al. Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. Blood 2005; 106: 95102.
  • 12
    Bepler G, Koehler A, Kiefer P, et al. Characterization of the state of differentiation of six established human nonsmall lung cancer lines. Differentiation 1988; 37: 158171.
  • 13
    Bepler G, Bading H, Heimann B, Kiefer P, Havemann K, Moelling K. Expression of p64c-myc neuroendocrine properties define three subclasses of small cell lung cancer. Oncogene 1989; 4: 4550.
  • 14
    Moreb JS, Muhoczy D, Ostmark B, Zucali JR. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmacol 2006; [Epub ahead of print].
  • 15
    Sreerama L, Sladek NE. Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem Pharmacol 1993; 45: 24872505.
  • 16
    Szeto W, Jiang W, Tice DA, Rubinfeld B, Hollingshead PG, Fong SE, Dugger DL, Pham T, Yansura DG, Wong TA, Grimaldi JC, Corpuz RT, Singh JS, Frantz GD, Devaux B, Crowley CW, Schwall RH, Eberhard DA, Tastelli L, Polakis P, Pennica D. Overexpression of the retinoic aci-responsive gene stra6 in human cancers and its synergistic induction by Wnt-1 and retinoic acid. Cancer Res 2001; 61: 41974205.
  • 17
    Sreerama L, Norman SE. Three different stable human breast adenocarcinoma sublines that overexpress ALDH3A1 and certain other enzymes, apparently as a consequence of constitutively upregulated gene transcription mediated by transactivated EpREs (electrophile responsive elements) present in the 5′-upstream regions of these genes. Chem Biol Interact 2001; 130–132: 247260.
  • 18
    Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 1984; 44: 51565160.
  • 19
    Manthey CL, Landkamer GJ, Sladek NE. Identification of the mouse aldehyde dehydrogenases important in aldophosphamide detoxification. Cancer Res 1990; 50: 49915002.
  • 20
    Sreerama L, Sladek NE. Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem Pharmacol 1993; 45: 24872505.
  • 21
    von Eitzen U, Meier-Tackmann D, Agarwal DP, Goedde HW. Detoxification of cyclophosphamide by human aldehyde dehydrogenase isozymes. Cancer Lett 1994; 76: 4549.
  • 22
    Yoshida A, Rzhetsky A, Hsu LC, Chang C. Human aldehyde dehydrogenase gene family. Eur J Biochem 1998; 251: 549557.
  • 23
    Storms RW, Trujillo AP, Springer JB, Shah L, Colvin OM, Ludeman SM, Smith C. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Cell Biol 1999; 96: 91189123.
  • 24
    Jones RJ, Barber JP, Vala MS, Collector MI, Kaufmann SH, Ludeman SM, Colvin OM, Hilton J. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995; 85: 27422746.
  • 25
    Armstrong L, Stojkovic M, Dimmick I, Ahmad S, Stojkovic P, Hole N, Lako M. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 2004; 22: 11421151.
  • 26
    Hess DA, Meyerrose TE, Wirthlin L, Craft TP, Herrbrich PE, Creer MH, Nolta JA. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004; 104: 16481655.
  • 27
    Pearce DJ, Taussig D, Simpson C, Allen K, Rohatiner AZ, Lister TA, Bonnet D. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005; 23: 752760.
  • 28
    Storms RW, Green PD, Safford KM, Niedzwiecki D, Cogle CR, Colvin OM, Chao NJ, Rice HE, Smith CA. Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. Blood 2005; 106: 95102.
  • 29
    Lioznov MV, Freiberger P, Kroger N, Zander AR Fehse B. Aldehyde dehydrogenase activity as a marker for the quality of hematopoietic stem cell transplants. Bone Marrow Transplant 2005; 35: 909914.
  • 30
    Soltysova A, Altanerova V, Altaner C. Cancer stem cells. Neoplasma 2005; 52: 436440.
  • 31
    Wang JCY, Dick JE. Cancer stem cells: Lessons from leukemia. Trends Cell Biol 2005; 15: 494501.
  • 32
    Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. PNAS 2004; 101: 1422814233.
  • 33
    Bender Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121: 823835.